FDA Approves New Injectable Drug for Chemotherapy Nausea Prevention

The U.S. FDA has granted approval for Aprepitant Injectable Emulsion, offering a new ready-to-use option to prevent nausea and vomiting in adults undergoing highly or moderately emetogenic chemotherapy. This formulation simplifies administration for healthcare professionals and avoids polysorbate-80. It provides an additional tool in managing a common and distressing side effect of cancer treatment.